Should You Buy Alibaba Stock Despite the Risks?
Markets rebounded slightly after U.S. President Donald Trump announced a…
Sell
37
EBS Quote, Financials, Valuation and Earnings
Last price:
$5.36
Seasonality move
:
28.59%
Day range:
$4.88 - $5.10
52-week range:
$1.82 - $15.10
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.26x
P/B ratio:
0.56x
Volume:
1.1M
Avg. volume:
1.2M
1-year change:
117.47%
Market cap:
$270.6M
Revenue:
$1B
EPS (TTM):
-$3.73
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
EBS
Emergent BioSolutions
|
$218.5M | $1.14 | -25.27% | -47.82% | $13.50 |
|
ADMA
ADMA Biologics
|
$116.4M | $0.14 | 42.17% | 75% | $25.74 |
|
CARA:DL
Cara Therapeutics(DELISTED)
|
-- | -- | 813.82% | -- | -- |
|
OCGN
Ocugen
|
-- | -$0.06 | -100% | -- | $6.75 |
|
OCUL
Ocular Therapeutix
|
$16.9M | -$0.28 | 16.58% | -42.86% | $17.50 |
|
TGTX
TG Therapeutics
|
$117.4M | $0.16 | 77.29% | 743.75% | $43.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
EBS
Emergent BioSolutions
|
$4.98 | $13.50 | $270.6M | -- | $0.00 | 0% | 0.26x |
|
ADMA
ADMA Biologics
|
$21.73 | $25.74 | $5.2B | 26.50x | $0.00 | 0% | 12.37x |
|
CARA:DL
Cara Therapeutics(DELISTED)
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
OCGN
Ocugen
|
$0.72 | $6.75 | $209.4M | -- | $0.00 | 0% | 47.91x |
|
OCUL
Ocular Therapeutix
|
$7.85 | $17.50 | $1.2B | -- | $0.00 | 0% | 19.49x |
|
TGTX
TG Therapeutics
|
$39.49 | $43.00 | $6.2B | 282.07x | $0.00 | 0% | 18.80x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
EBS
Emergent BioSolutions
|
57.89% | 9.971 | 127.78% | 1.56x |
|
ADMA
ADMA Biologics
|
17.17% | 2.782 | 1.78% | 2.76x |
|
CARA:DL
Cara Therapeutics(DELISTED)
|
-- | -3.140 | -- | -- |
|
OCGN
Ocugen
|
49.18% | 1.424 | 12.22% | 2.71x |
|
OCUL
Ocular Therapeutix
|
17.85% | 2.429 | 5.09% | 10.26x |
|
TGTX
TG Therapeutics
|
52.36% | 1.750 | 5.21% | 4.85x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
EBS
Emergent BioSolutions
|
$71.3M | -$9.5M | -14.34% | -35.42% | -6.76% | -$81.6M |
|
ADMA
ADMA Biologics
|
$63.3M | $38.3M | 60.85% | 93.41% | 31.98% | $47.5M |
|
CARA:DL
Cara Therapeutics(DELISTED)
|
-- | -- | -- | -- | -- | -- |
|
OCGN
Ocugen
|
-- | -$13.8M | -136.46% | -171.04% | -1811.52% | -$10.4M |
|
OCUL
Ocular Therapeutix
|
$15.9M | -$50.6M | -51.22% | -62.66% | -265.09% | -$39.6M |
|
TGTX
TG Therapeutics
|
$92.8M | $29.9M | 6.86% | 12.81% | 30.05% | -$25.7M |
Emergent BioSolutions vs. Competitors
-
Which has Higher Returns EBS or ADMA?
ADMA Biologics has a net margin of -16.54% compared to Emergent BioSolutions's net margin of 95.19%. Emergent BioSolutions's return on equity of -35.42% beat ADMA Biologics's return on equity of 93.41%.
Company Gross Margin Earnings Per Share Invested Capital EBSEmergent BioSolutions37.67% -$0.58 $1.1B ADMAADMA Biologics53.88% $0.46 $421.4M -
What do Analysts Say About EBS or ADMA?
Emergent BioSolutions has a consensus price target of $13.50, signalling upside risk potential of 171.08%. On the other hand ADMA Biologics has an analysts' consensus of $25.74 which suggests that it could grow by 18.45%. Given that Emergent BioSolutions has higher upside potential than ADMA Biologics, analysts believe Emergent BioSolutions is more attractive than ADMA Biologics.
Company Buy Ratings Hold Ratings Sell Ratings EBSEmergent BioSolutions1 0 0 ADMAADMA Biologics3 1 0 -
Is EBS or ADMA More Risky?
Emergent BioSolutions has a beta of 2.141, which suggesting that the stock is 114.124% more volatile than S&P 500. In comparison ADMA Biologics has a beta of 0.527, suggesting its less volatile than the S&P 500 by 47.277%.
-
Which is a Better Dividend Stock EBS or ADMA?
Emergent BioSolutions has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ADMA Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Emergent BioSolutions pays -- of its earnings as a dividend. ADMA Biologics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EBS or ADMA?
Emergent BioSolutions quarterly revenues are $189.3M, which are larger than ADMA Biologics quarterly revenues of $117.5M. Emergent BioSolutions's net income of -$31.3M is lower than ADMA Biologics's net income of $111.9M. Notably, Emergent BioSolutions's price-to-earnings ratio is -- while ADMA Biologics's PE ratio is 26.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Emergent BioSolutions is 0.26x versus 12.37x for ADMA Biologics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EBSEmergent BioSolutions0.26x -- $189.3M -$31.3M ADMAADMA Biologics12.37x 26.50x $117.5M $111.9M
-
Which has Higher Returns EBS or CARA:DL?
Cara Therapeutics(DELISTED) has a net margin of -16.54% compared to Emergent BioSolutions's net margin of --. Emergent BioSolutions's return on equity of -35.42% beat Cara Therapeutics(DELISTED)'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital EBSEmergent BioSolutions37.67% -$0.58 $1.1B CARA:DLCara Therapeutics(DELISTED)-- -- -- -
What do Analysts Say About EBS or CARA:DL?
Emergent BioSolutions has a consensus price target of $13.50, signalling upside risk potential of 171.08%. On the other hand Cara Therapeutics(DELISTED) has an analysts' consensus of -- which suggests that it could fall by --. Given that Emergent BioSolutions has higher upside potential than Cara Therapeutics(DELISTED), analysts believe Emergent BioSolutions is more attractive than Cara Therapeutics(DELISTED).
Company Buy Ratings Hold Ratings Sell Ratings EBSEmergent BioSolutions1 0 0 CARA:DLCara Therapeutics(DELISTED)0 0 0 -
Is EBS or CARA:DL More Risky?
Emergent BioSolutions has a beta of 2.141, which suggesting that the stock is 114.124% more volatile than S&P 500. In comparison Cara Therapeutics(DELISTED) has a beta of 0.414, suggesting its less volatile than the S&P 500 by 58.556%.
-
Which is a Better Dividend Stock EBS or CARA:DL?
Emergent BioSolutions has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cara Therapeutics(DELISTED) offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Emergent BioSolutions pays -- of its earnings as a dividend. Cara Therapeutics(DELISTED) pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EBS or CARA:DL?
Emergent BioSolutions quarterly revenues are $189.3M, which are larger than Cara Therapeutics(DELISTED) quarterly revenues of --. Emergent BioSolutions's net income of -$31.3M is higher than Cara Therapeutics(DELISTED)'s net income of --. Notably, Emergent BioSolutions's price-to-earnings ratio is -- while Cara Therapeutics(DELISTED)'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Emergent BioSolutions is 0.26x versus -- for Cara Therapeutics(DELISTED). Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EBSEmergent BioSolutions0.26x -- $189.3M -$31.3M CARA:DLCara Therapeutics(DELISTED)-- -- -- --
-
Which has Higher Returns EBS or OCGN?
Ocugen has a net margin of -16.54% compared to Emergent BioSolutions's net margin of -1816.75%. Emergent BioSolutions's return on equity of -35.42% beat Ocugen's return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital EBSEmergent BioSolutions37.67% -$0.58 $1.1B OCGNOcugen-- -$0.05 $58.3M -
What do Analysts Say About EBS or OCGN?
Emergent BioSolutions has a consensus price target of $13.50, signalling upside risk potential of 171.08%. On the other hand Ocugen has an analysts' consensus of $6.75 which suggests that it could grow by 841.42%. Given that Ocugen has higher upside potential than Emergent BioSolutions, analysts believe Ocugen is more attractive than Emergent BioSolutions.
Company Buy Ratings Hold Ratings Sell Ratings EBSEmergent BioSolutions1 0 0 OCGNOcugen2 0 0 -
Is EBS or OCGN More Risky?
Emergent BioSolutions has a beta of 2.141, which suggesting that the stock is 114.124% more volatile than S&P 500. In comparison Ocugen has a beta of 3.784, suggesting its more volatile than the S&P 500 by 278.402%.
-
Which is a Better Dividend Stock EBS or OCGN?
Emergent BioSolutions has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocugen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Emergent BioSolutions pays -- of its earnings as a dividend. Ocugen pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EBS or OCGN?
Emergent BioSolutions quarterly revenues are $189.3M, which are larger than Ocugen quarterly revenues of $764K. Emergent BioSolutions's net income of -$31.3M is lower than Ocugen's net income of -$13.9M. Notably, Emergent BioSolutions's price-to-earnings ratio is -- while Ocugen's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Emergent BioSolutions is 0.26x versus 47.91x for Ocugen. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EBSEmergent BioSolutions0.26x -- $189.3M -$31.3M OCGNOcugen47.91x -- $764K -$13.9M
-
Which has Higher Returns EBS or OCUL?
Ocular Therapeutix has a net margin of -16.54% compared to Emergent BioSolutions's net margin of -283.27%. Emergent BioSolutions's return on equity of -35.42% beat Ocular Therapeutix's return on equity of -62.66%.
Company Gross Margin Earnings Per Share Invested Capital EBSEmergent BioSolutions37.67% -$0.58 $1.1B OCULOcular Therapeutix92.8% -$0.29 $383.8M -
What do Analysts Say About EBS or OCUL?
Emergent BioSolutions has a consensus price target of $13.50, signalling upside risk potential of 171.08%. On the other hand Ocular Therapeutix has an analysts' consensus of $17.50 which suggests that it could grow by 122.93%. Given that Emergent BioSolutions has higher upside potential than Ocular Therapeutix, analysts believe Emergent BioSolutions is more attractive than Ocular Therapeutix.
Company Buy Ratings Hold Ratings Sell Ratings EBSEmergent BioSolutions1 0 0 OCULOcular Therapeutix6 0 0 -
Is EBS or OCUL More Risky?
Emergent BioSolutions has a beta of 2.141, which suggesting that the stock is 114.124% more volatile than S&P 500. In comparison Ocular Therapeutix has a beta of 1.491, suggesting its more volatile than the S&P 500 by 49.133%.
-
Which is a Better Dividend Stock EBS or OCUL?
Emergent BioSolutions has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocular Therapeutix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Emergent BioSolutions pays -- of its earnings as a dividend. Ocular Therapeutix pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EBS or OCUL?
Emergent BioSolutions quarterly revenues are $189.3M, which are larger than Ocular Therapeutix quarterly revenues of $17.1M. Emergent BioSolutions's net income of -$31.3M is higher than Ocular Therapeutix's net income of -$48.4M. Notably, Emergent BioSolutions's price-to-earnings ratio is -- while Ocular Therapeutix's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Emergent BioSolutions is 0.26x versus 19.49x for Ocular Therapeutix. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EBSEmergent BioSolutions0.26x -- $189.3M -$31.3M OCULOcular Therapeutix19.49x -- $17.1M -$48.4M
-
Which has Higher Returns EBS or TGTX?
TG Therapeutics has a net margin of -16.54% compared to Emergent BioSolutions's net margin of 21.57%. Emergent BioSolutions's return on equity of -35.42% beat TG Therapeutics's return on equity of 12.81%.
Company Gross Margin Earnings Per Share Invested Capital EBSEmergent BioSolutions37.67% -$0.58 $1.1B TGTXTG Therapeutics85.77% $0.15 $466.8M -
What do Analysts Say About EBS or TGTX?
Emergent BioSolutions has a consensus price target of $13.50, signalling upside risk potential of 171.08%. On the other hand TG Therapeutics has an analysts' consensus of $43.00 which suggests that it could grow by 8.89%. Given that Emergent BioSolutions has higher upside potential than TG Therapeutics, analysts believe Emergent BioSolutions is more attractive than TG Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings EBSEmergent BioSolutions1 0 0 TGTXTG Therapeutics5 0 0 -
Is EBS or TGTX More Risky?
Emergent BioSolutions has a beta of 2.141, which suggesting that the stock is 114.124% more volatile than S&P 500. In comparison TG Therapeutics has a beta of 2.139, suggesting its more volatile than the S&P 500 by 113.867%.
-
Which is a Better Dividend Stock EBS or TGTX?
Emergent BioSolutions has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TG Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Emergent BioSolutions pays -- of its earnings as a dividend. TG Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EBS or TGTX?
Emergent BioSolutions quarterly revenues are $189.3M, which are larger than TG Therapeutics quarterly revenues of $108.2M. Emergent BioSolutions's net income of -$31.3M is lower than TG Therapeutics's net income of $23.3M. Notably, Emergent BioSolutions's price-to-earnings ratio is -- while TG Therapeutics's PE ratio is 282.07x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Emergent BioSolutions is 0.26x versus 18.80x for TG Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EBSEmergent BioSolutions0.26x -- $189.3M -$31.3M TGTXTG Therapeutics18.80x 282.07x $108.2M $23.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is Intel Struggling Against AMD?
Due to its disappointing reports, so-so management, and lack of…
Will PayPal Stock Recover or Keep Sliding?
Payments platform behemoth PayPal Holdings, Inc. (NASDAQ:PYPL) is going through…
Stock Ideas
Buy
56
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 34x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
49
Is NVDA Stock a Buy?
Market Cap: $2.5T
P/E Ratio: 35x
Alerts
Buy
71
PEGA alert for Apr 24
Pegasystems [PEGA] is up 3.13% over the past day.
Buy
67
SMMT alert for Apr 24
Summit Therapeutics [SMMT] is up 10.38% over the past day.
Sell
36
ENPH alert for Apr 24
Enphase Energy [ENPH] is up 1.44% over the past day.
